nach oben

Der Nervenarzt

Erschienen in:

19.08.2019 | Demenz | Leitthema

Neuroinflammation als Motor der Alzheimer-Erkrankung

verfasst von: Sergio Castro-Gomez, Julius Binder, Prof. Dr. Michael T. Heneka

Erschienen in: Der Nervenarzt | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die sporadische Alzheimer-Krankheit ist die häufigste neurodegenerative Erkrankung und stellt ein sehr relevantes Problem der öffentlichen Gesundheitsversorgung mit einer verheerenden wirtschaftlichen Belastung für die Industrieländer dar. Neue Erkenntnisse aus experimentellen, epidemiologischen, bildmorphologischen und genomweiten Assoziationsstudien („genome wide association studies“, GWAS) unterstreichen die Rolle des angeborenen Immunsystems in der Pathophysiologie dieser Krankheit. Im folgenden Artikel werden die neu entdeckten krankheitsassoziierten Gene sowie die experimentellen Beweise für die Rolle der Mikrogliazellen bei der Entstehung des Fortschreitens der Alzheimer-Krankheit diskutiert und zusammengefasst. Die Entdeckung verschiedener pathologieassoziierten Mikrogliaphänotypen sowie neuer molekularer Akteure wird die Entwicklung neuer präventiver und therapeutischer Strategien durch die Modulation der Neuroinflammation bei neurodegenerativen Erkrankungen ermöglichen.

Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428–435CrossRefPubMed

Kierdorf K et al (2013) Microglia emerge from erythromyeloid precursors via Pu.1-and Irf8-dependent pathways. Nat Neurosci 16:273–280CrossRefPubMed

Askew K et al (2017) Coupled proliferation and Apoptosis maintain the rapid turnover of Microglia in the adult brain. Cell Rep 18:391–405CrossRefPubMedPubMedCentral

Benarroch EE (2013) Microglia: Multiple roles in surveillance, circuit shaping, and response to injury. Baillieres Clin Neurol 81:1079–1088

Pierre WC et al (2017) Neonatal microglia: the cornerstone of brain fate. Brain Behav Immun 59:333–345CrossRefPubMed

Parkhurst CN et al (2013) Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155:1596–1609CrossRefPubMedPubMedCentral

Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–344CrossRefPubMed

Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) VIEWPOINT an English translation of alzheimer’s 1907 paper „Über eine eigenartige Erkrankung der Hirnrinde“. Clin Anat 8:429–443CrossRefPubMed

Heneka MT et al (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14:388–405CrossRefPubMedPubMedCentral

10.

Wang J et al (2015) Anti-inflammatory drugs and risk of alzheimer’s disease: an updated systematic review and meta-analysis. J Alzheimer’s Dis 44:385–396CrossRef

11.

I. TJ, E. EW, S. DM, L. KM (2010) Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 304:1787–1794CrossRef

12.

Scarmeas N et al (2009) Physical activity, diet, and risk of Alzheimer disease. JAMA 302:627–637CrossRefPubMedPubMedCentral

13.

Hicks A, James A, Spitz G, Ponsford J (2019) Traumatic brain injury as a risk factor for dementia and alzheimer’s disease: critical review of study methodologies. J Neurotrauma. https://doi.org/10.1089/neu.2018.6346 CrossRefPubMed

14.

Kwiatek-Majkusiak J et al (2015) Relationships between typical histopathological hallmarks and the ferritin in the hippocampus from patients with Alzheimer’s disease. Acta Neurobiol Exp (wars) 75:391–398

15.

Zeineh MM et al (2015) Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease. Neurobiol Aging 36:2483–2500CrossRefPubMedPubMedCentral

16.

Cosenza-Nashat M et al (2009) Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol 35:306–328CrossRefPubMed

17.

Kreisl WC et al (2013) In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain 136:2228–2238CrossRefPubMedPubMedCentral

18.

Leroy C et al (2016) Early and protective microglial activation in Alzheimer’s disease : a prospective study using 18 F-DPA-714 PET imaging. Brain:1252–1264. https://doi.org/10.1093/brain/aww017 CrossRefPubMed

19.

Kunkle BW et al (2019) Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet 51:414–430CrossRefPubMedPubMedCentral

20.

Jansen IE et al (2019) Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet 51:404–413CrossRefPubMedPubMedCentral

21.

Lambert JC et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45:1452–1458CrossRefPubMedPubMedCentral

22.

Huang K et al (2017) A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease. Nat Neurosci 20:1052–1061CrossRefPubMedPubMedCentral

23.

Guerreiro R et al (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368:117–127CrossRefPubMed

24.

Jonsson T et al (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368:107–116CrossRefPubMed

25.

Wang S, Colonna M (2019) Microglia in Alzheimer’s disease: A target for immunotherapy. J Leukoc Biol:1–9. https://doi.org/10.1002/JLB.MR0818-319R CrossRefPubMed

26.

Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, Sleegers K, Vronskaya M, Ruiz A, Graham RR, Olaso R, Hoffmann P (2017) S. G. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat Genet. https://doi.org/10.1038/ng.3916 CrossRefPubMedPubMedCentral

27.

Huang Y, Weisgraber KH, Mucke L, Mahley RW (2004) Apolipoprotein E. J Mol Neurosci 23:189–204CrossRefPubMed

28.

Keren-shaul H et al (2017) A unique Microglia type associated with restricting development of alzheimer’s disease article A unique Microglia type associated with restricting development of alzheimer’s disease. Cell 169(7):1276–1290.e1CrossRefPubMed

29.

Krasemann S et al (2017) The TREM2-APOE pathway drives the Transcriptional phenotype of dysfunctional Microglia in Neurodegenerative diseases. Immunity 47:566–581.e9CrossRefPubMedPubMedCentral

30.

Mathys H et al (2019) Single-cell transcriptomic analysis of Alzheimer’s disease. Nature. https://doi.org/10.1038/s41586-019-1195-2 CrossRefPubMedPubMedCentral

31.

Dickson DW et al (1988) Alzheimer’s disease. A double-labeling immunohistochemical study of senile plaques. Am J Pathol 132:86–101PubMedPubMedCentral

32.

Martin E, Boucher C, Fontaine B, Delarasse C (2017) Distinct inflammatory phenotypes of microglia and monocyte-derived macrophages in Alzheimer’s disease models: effects of aging and amyloid pathology. Aging Cell 16:27–38CrossRefPubMed

33.

Venegas C, Heneka MT (2017) Danger-associated molecular patterns in Alzheimer’s disease. J Leukoc Biol 101:87–98CrossRefPubMed

34.

Du Yan S et al (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature 382:685–691CrossRefPubMed

35.

Landreth GE, Reed-geaghan EG (2009) Toll-like receptors: roles in infection and neuropathology Bd. 336. Springer, Berlin Heidelberg

36.

El Khoury J et al (1996) Scavenger receptor-mediated adhesion of microglia to β‑amyloid fibrils. Nature 382:716–719CrossRefPubMed

37.

Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE (2003) A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 23:2665–2674CrossRefPubMedPubMedCentral

38.

Halle A et al (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol 9:857–865CrossRefPubMedPubMedCentral

39.

Sheedy FJ et al (2013) CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 14:812–820CrossRefPubMedPubMedCentral

40.

Venegas C et al (2017) Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature 552:355–361CrossRefPubMed

41.

Asai H et al (2015) Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 18:1584–1593CrossRefPubMedPubMedCentral

42.

Liddelow SA et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487CrossRefPubMedPubMedCentral

43.

Bisht K et al (2016) Dark microglia: a new phenotype predominantly associated with pathological states. Glia 64:826–839CrossRefPubMedPubMedCentral

44.

Füger P et al (2017) Microglia turnover with aging and in an Alzheimer’s model via long-term in vivo single-cell imaging. Nat Neurosci 20:1371–1376CrossRefPubMed

45.

Olmos-Alonso A et al (2016) Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Brain 139:891–907CrossRefPubMedPubMedCentral

46.

Kamphuis W, Orre M, Kooijman L, Dahmen M, Hol EM (2012) Differential cell proliferation in the cortex of the APPswePS1dE9 Alzheimer’s disease mouse model. Glia 60:615–629CrossRefPubMed

47.

Frank S, Copanaki E, Burbach GJ, Müller UC, Deller T (2009) Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice. Neurosci Lett 453:41–44CrossRefPubMed

48.

Song M, Jin J, Lim JE et al (2011) TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer’s disease. J Neuroinflammation 8:92. https://doi.org/10.1186/1742-2094-8-92 CrossRefPubMedPubMedCentral

49.

Reed-Geaghan EG, Reed QW, Cramer PE, Landreth GE (2010) Deletion of CD14 attenuates alzheimer’s disease pathology by influencing the brain’s inflammatory milieu. J Neurosci 30:15369–15373CrossRefPubMedPubMedCentral

50.

Wang YL et al (2013) Toll-like receptor 9 promoter polymorphism is associated with decreased risk of Alzheimer’s disease in Han Chinese. J Neuroinflammation 10:1–5CrossRef

51.

Harold D et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41:1088–1093CrossRefPubMedPubMedCentral

52.

Lambert JC et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41:1094–1099CrossRefPubMed

53.

Hong S et al (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 80(352):712–716CrossRef

54.

Yin C et al (2019) ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat Med 25:496–506CrossRefPubMedPubMedCentral

55.

Griffin WST, Mrak RE (2002) Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer’s disease. J Leukoc Biol 72:233–238PubMed

56.

Ghosh S et al (2013) Sustained Interleukin-1 Overexpression exacerbates tau pathology despite reduced Amyloid burden in an alzheimer’s mouse model. J Neurosci 33:5053–5064CrossRefPubMedPubMedCentral

57.

Chakrabarty P et al (2009) Massive gliosis induced by interleukin-6 suppresses Aβ deposition in vivo : evidence against inflammation as a driving force for amyloid deposition. Faseb J 24:548–559CrossRefPubMed

58.

Chakrabarty P et al (2010) IFN- promotes complement expression and attenuates Amyloid plaque deposition in Amyloid precursor protein Transgenic mice. J Immunol 184:5333–5343CrossRefPubMed

59.

Montgomery SL et al (2011) Ablation of TNF-RI/RII expression in Alzheimer’s disease mice leads to an unexpected enhancement of pathology: Implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain. Am J Pathol 179:2053–2070CrossRefPubMedPubMedCentral

60.

Vom Berg J et al (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s diseasea-like pathology and cognitive decline. Nat Med 18:1812–1819CrossRefPubMed

61.

Zetterberg H, Andreasen N, Blennow K (2004) Increased cerebrospinal fluid levels of transforming growth factor-β1 in Alzheimer’s disease. Neurosci Lett 367:194–196CrossRefPubMed

62.

Tesseur I et al (2006) Deficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer’s pathology. J Clin Invest 116:3060–3069CrossRefPubMedPubMedCentral

63.

Chakrabarty P et al (2015) IL-10 alters Immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85:519–533CrossRefPubMedPubMedCentral

64.

Ulland TK, Colonna M (2018) TREM2—a key player in microglial biology and Alzheimer disease. Nat Rev Neurol 14:667–675CrossRefPubMed

65.

Hsieh CL et al (2009) A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109:1144–1156CrossRefPubMedPubMedCentral

66.

Suárez-Calvet M et al (2016) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury markers. Embo Mol Med. https://doi.org/10.15252/emmm.201506123 CrossRefPubMedPubMedCentral

67.

Gurvit H et al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6:243ra86–243ra86CrossRefPubMed

68.

Ulland TK et al (2017) TREM2 maintains mcroglial metabolic fitness in alzheimer’s disease. Cell 170:649–663.e13CrossRefPubMedPubMedCentral

69.

Wang Y et al (2014) Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener 9:20. https://doi.org/10.1186/1750-1326-9-20 CrossRef

70.

Mazaheri F et al (2017) TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. Embo Rep 18:1186–1198CrossRefPubMedPubMedCentral

71.

Song WM et al (2018) Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med 215:745–760CrossRefPubMedPubMedCentral

72.

Jiang T et al (2015) Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice. Neurobiol Aging 36:3176–3186CrossRefPubMed

73.

Cronk JC et al (2018) Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia. J Exp Med 215:1627–1647CrossRefPubMedPubMedCentral

74.

Marsh SE et al (2016) The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A 113:E1316–E1325CrossRefPubMedPubMedCentral

75.

Katsimpardi L et al (2014) Vascular and Neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 80(344):630–634CrossRef

76.

Domercq M, Vazquez-Villoldo N, Matute C (2013) Neurotransmitter signaling in the pathophysiology of microglia. Front Cell Neurosci 7:1–17

77.

Kim TS et al (2008) Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett 436:196–200CrossRefPubMed

78.

Bhaskar K et al (2010) Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68:19–31CrossRefPubMedPubMedCentral

79.

Heneka MT et al (2010) Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A 107:6058–6063CrossRefPubMedPubMedCentral

80.

Martorell AJ et al (2019) Multi-sensory gamma stimulation ameliorates alzheimer’s-associated pathology and improves cognition. Cell 177:256–271.e22CrossRefPubMedPubMedCentral

Titel: Neuroinflammation als Motor der Alzheimer-Erkrankung
verfasst von: Sergio Castro-Gomez
Julius Binder
Prof. Dr. Michael T. Heneka
Publikationsdatum: 19.08.2019
Verlag: Springer Medizin
Schlagwörter: Demenz
Morbus Alzheimer
Pathologie
Demenz
Morbus Alzheimer
Erschienen in: Der Nervenarzt / Ausgabe 9/2019
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-019-0778-3

Springer Medizin

Neuroinflammation als Motor der Alzheimer-Erkrankung

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Chirurginnen und Chirurgen sind stark suizidgefährdet

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

CME: Psychische Gesundheit von Ärzten

Quo vadis Alzheimer?

Nachruf auf Prof. Dr. Werner Janzarik (1920–2019)

Hat die Alzheimer-Forschung versagt?

Anti-Tau-Therapien – was können wir erwarten?

Mitteilungen der DGPPN 9/2019

Neu in den Fachgebieten Neurologie und Psychiatrie

Chirurginnen und Chirurgen sind stark suizidgefährdet

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind